Alivus Life Sciences (BOM:543322) Other Financing: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:543322 Alivus Life Sciences Ltd BOM:543322
84 GF Score
Price ₹1,095.45
GF Value ₹1,021.50
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Alivus Life Sciences Other Financing?

Alivus Life Sciences BOM:543322 -2.17% 84 Other Financing is ₹0 Mil as of Mar. 2026. GuruFocus rates BOM:543322 with a GF Score™ of 84/100 and a GF Value™ of ₹1,021.50 (Fairly Valued). The stock has 5 warning signs investors should review.

Alivus Life Sciences's Other Financing for the three months ended in Mar. 2026 was ₹0 Mil.

Alivus Life Sciences's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Alivus Life Sciences Other Financing Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences Other Financing Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial -277.64 -5.47 -15.46 -24.14 -53.72

Alivus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:543322
84GF Score
Alivus Life Sciences Ltd BOM:543322
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₹0 Mil mean?
Alivus Life Sciences (BOM:543322) has a Other Financing of ₹0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Alivus Life Sciences and its competitors.
Is Alivus Life Sciences' Other Financing too high?
Alivus Life Sciences' current Other Financing is ₹0 Mil. Overall, Alivus Life Sciences has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Other Financing compare to ZTS?
Alivus Life Sciences' Other Financing of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Alivus Life Sciences and its competitors. Alivus Life Sciences's current Other Financing is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (BOM:543322) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,021.50, compared to a current price of ₹1,095.45 — trading 7.2% above its estimated fair value. The current Other Financing is ₹0 Mil. Alivus Life Sciences' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Alivus Life Sciences (BOM:543322), the current Other Financing is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (BOM:543322) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,095.45 is trading 7.2% above its estimated GF Value™ of ₹1,021.50. GuruFocus considers Alivus Life Sciences to be Fairly Valued.

Key valuation signals for BOM:543322:

  • Other Financing: ₹0 Mil
  • GF Value™: ₹1,021.50 vs. price of ₹1,095.45 (7.2% above fair value)
  • GF Score™: 84/100 with 5 warning signs

No single metric tells the full story. See the BOM:543322 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges ALIVUS:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
84GF Score

Get the complete analysis for BOM:543322

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,095.45
Price
₹1,021.50
GF Value